Jay Friedman

3.5k citations

55 papers · 2.6k indexed · h-index 27

Impact in

Immunology top 2%
- Immune cells in cancer
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer-related Molecular Pathways

Papers in ⓘ

Oncology 36
- Cancer Immunotherapy and Biomarkers 17
- Cancer-related Molecular Pathways 8
- CAR-T cell therapy research 8
- Cancer Cells and Metastasis 3
Immunology 26
- Immune Cell Function and Interaction 9
- Immunotherapy and Immune Responses 9
- Immune cells in cancer 7

Co-authors: Carter Van Waes (20 shared papers)Clint Allen (28 shared papers)Paúl E. Clavijo (16 shared papers)Zhong Chen (10 shared papers)Ellen Moore (10 shared papers)Yvette Robbins (12 shared papers)Jeffrey Schlom (9 shared papers)Priya Mohanty (3 shared papers)
Journals: Clinical Cancer Research (6 papers)OncoImmunology (4 papers)Cancer Research (4 papers)Oral Oncology (4 papers)Journal for ImmunoTherapy of Cancer (3 papers)
Partner nations: United States Germany Taiwan

In The Last Decade

Jay Friedman

55 papers receiving 2.5k citations

Peers

Countries citing papers authored by Jay Friedman

Since Specialization

Citations

This map shows the geographic impact of Jay Friedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Friedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Friedman more than expected).

Fields of papers citing papers by Jay Friedman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Friedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Friedman. The network helps show where Jay Friedman may publish in the future.

Co-authors

The 25 scholars most cited alongside Jay Friedman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jay Friedman Line = papers co-authored together Jay Friedman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models Clinical Cancer Research ·Sarah Greene, Yvette Robbins, Wojciech K. Mydlarz, Angel P. Huynh, Nicole C. Schmitt, Jay Friedman, Lucas A. Horn, Claudia Palena, Jeffrey Schlom, Dean Y. Maeda, John A. Zebala, Paúl E. Clavijo, Clint Allen	2019	217
2	Differential Effects of Cream, Glucose, and Orange Juice on Inflammation, Endotoxin, and the Expression of Toll-Like Receptor-4 and Suppressor of Cytokine Signaling-3 Diabetes Care ·Rupali Deopurkar, Husam Ghanim, Jay Friedman, Sanaa Abuaysheh, Chang Ling Sia, Priya Mohanty, Prabhakar Viswanathan, Ajay Chaudhuri, Paresh Dandona	2010	202
3	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy JCI Insight ·Lillian Sun, Paúl E. Clavijo, Yvette Robbins, Priya Patel, Jay Friedman, Sarah Greene, Rita Das, Chris Silvin, Carter Van Waes, Lucas A. Horn, Jeffrey Schlom, Claudia Palena, Dean Y. Maeda, John A. Zebala, Clint Allen	2019	188
4	Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ Cancer Research ·Ruth J. Davis, Ellen Moore, Paúl E. Clavijo, Jay Friedman, Harrison Cash, Zhong Chen, Chris Silvin, Carter Van Waes, Clint Allen	2017	178
5	EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy Expert Opinion on Therapeutic Targets ·Christian Freudlsperger, (unknown), Jay Friedman, Vishnu R. Kannabiran, Zhong Chen, Carter Van Waes	2010	146
6	Glucose ingestion induces an increase in intranuclear nuclear factor κB, a fall in cellular inhibitor κB, and an increase in tumor necrosis factor α messenger RNA by mononuclear cells in healthy human subjects Metabolism ·Ahmad Aljada, Jay Friedman, Husam Ghanim, Priya Mohanty, Deborah Hofmeyer, Ajay Chaudhuri, Paresh Dandona	2006	127
7	Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors Cancer Immunology Research ·Tadanobu Nagaya, Jay Friedman, Yasuhiro Maruoka, Fusa Ogata, Shuhei Okuyama, Paúl E. Clavijo, Peter L. Choyke, Clint Allen, Hisataka Kobayashi	2019	123
8	PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation OncoImmunology ·Megan V. Morisada, Paúl E. Clavijo, Ellen Moore, Lillian Sun, Michael M. Chamberlin, Carter Van Waes, James W. Hodge, James B. Mitchell, Jay Friedman, Clint Allen	2017	106
9	ΔNp63 Versatilely Regulates a Broad NF-κB Gene Program and Promotes Squamous Epithelial Proliferation, Migration, and Inflammation Cancer Research ·Xinping Yang, Hai Lü, Bin Yan, Rose-Anne Romano, Yansong Bian, Jay Friedman, Praveen Duggal, Clint Allen, Ryan Chuang, Reza Ehsanian, Han Si, Satrajit Sinha, Carter Van Waes, Zhong Chen	2011	101
10	A signal network involving coactivated NF‐κB and STAT3 and altered p53 modulates BAX/BCL‐XL expression and promotes cell survival of head and neck squamous cell carcinomas International Journal of Cancer ·TL Lee, Jason Yeh, Jay Friedman, Bin Yan, Xinping Yang, Ning T. Yeh, Carter Van Waes, Zhong Chen	2008	89
11	Current and potential inflammation targeted therapies in head and neck cancer Current Opinion in Pharmacology ·Frederick Wang, Pattatheyil Arun, Jay Friedman, Zhong Chen, Carter Van Waes	2009	79
12	Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells Oncotarget ·Paúl E. Clavijo, Ellen Moore, Jianhong Chen, Ruth J. Davis, Jay Friedman, Young Kim, Carter Van Waes, Zhong Chen, Clint Allen	2017	73
13	Synthesis and Evaluation of Paclitaxel-Loaded Gold Nanoparticles for Tumor-Targeted Drug Delivery Bioconjugate Chemistry ·Giulio F. Paciotti, Jielu Zhao, Shugeng Cao, Peggy J. Brodie, Lawrence Tamarkin, Marja S. Huhta, Lonnie D. Myer, Jay Friedman, David G. I. Kingston	2016	72
14	A Novel Nuclear Factor-κB Gene Signature Is Differentially Expressed in Head and Neck Squamous Cell Carcinomas in Association with TP53 Status Clinical Cancer Research ·TL Lee, Xin Yang, Bin Yan, Jay Friedman, Praveen Duggal, Lorena Bagain, Gang Dong, Ning T. Yeh, Jie Wang, Jian Zhou, Abdel Elkahloun, Carter Van Waes, Zhong Chen	2007	66
15	Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101 Molecular Cancer Therapeutics ·Jianming Duan, Jay Friedman, Liesl Nottingham, Zhong Chen, Gulshan Ara, Carter Van Waes	2007	61
16	Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells Clinical Cancer Research ·Jay Friedman, Ellen Moore, Paul Zolkind, Yvette Robbins, Paúl E. Clavijo, Lillian Sun, Sarah Greene, Megan V. Morisada, Wojciech K. Mydlarz, Nicole C. Schmitt, James W. Hodge, Hans Schreiber, Carter Van Waes, Ravindra Uppaluri, Clint Allen	2019	57
17	Deficient TP53 Expression, Function, and Cisplatin Sensitivity Are Restored by Quinacrine in Head and Neck Cancer Clinical Cancer Research ·Jay Friedman, Liesl Nottingham, Praveen Duggal, Francisco G. Pernas, Bin Yan, Xin Yang, Zhong Chen, Carter Van Waes	2007	47
18	Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-κB and other signal transcription factors in head and neck squamous cell carcinoma Genome biology ·Bin Yan, Xinping Yang, TL Lee, Jay Friedman, Jun Tang, Carter Van Waes, Zhong Chen	2007	47
19	Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck Cancer Clinical Cancer Research ·Francisco G. Pernas, Clint Allen, Mary Winters, Bin Yan, Jay Friedman, Bhavana Dabir, Kunal Saigal, Gerhard S. Mundinger, Xiaojiang Xu, John C. Morris, Katherine R. Calvo, Carter Van Waes, Zhong Chen	2009	46
20	WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy OncoImmunology ·Lillian Sun, Ellen Moore, Rose Berman, Paúl E. Clavijo, Anthony D. Saleh, Zhong Chen, Carter Van Waes, John Davies, Jay Friedman, Clint Allen	2018	46

About Jay Friedman

Jay Friedman is a scholar working on Oncology, Immunology, Cancer Research, Molecular Biology and Otorhinolaryngology, having authored 55 papers that have together received 2.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (17 papers), Immune Cell Function and Interaction (9 papers), Immunotherapy and Immune Responses (9 papers), Cancer-related Molecular Pathways (8 papers), CAR-T cell therapy research (8 papers), NF-κB Signaling Pathways (7 papers), Immune cells in cancer (7 papers) and Cancer Cells and Metastasis (3 papers). The work is most often cited by research in Immunology (1.1k citations), Oncology (1.2k citations), Otorhinolaryngology (111 citations), Cancer Research (355 citations) and Molecular Biology (834 citations). Jay Friedman has collaborated with scholars based in United States, Germany and Taiwan. Frequent co-authors include Carter Van Waes, Clint Allen, Paúl E. Clavijo, Zhong Chen, Ellen Moore, Yvette Robbins, Jeffrey Schlom, Priya Mohanty, Paresh Dandona and Husam Ghanim. Their work appears in journals such as Clinical Cancer Research, OncoImmunology, Cancer Research, Oral Oncology and Journal for ImmunoTherapy of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact